(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
A Manual for Well known Western television Series- Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
- 6 Famous Urban communities for Shopping on the planet
- Tehran synagogue damaged by missile strike according to Iranian media
- Impact of NIH funding reductions felt in cancer and infectious disease trials
- Palestinian leader Abbas says elections only after Gaza war ends
- Stolen Renoir, Cézanne and Matisse were probably uninsured, market sources say
- UN mission says no evidence Hezbollah rearming in southern Lebanon
- Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
